STOCK TITAN
  1. Home
  2. News
  3. ZLAB

Zai Lab Limited - ZLAB STOCK NEWS

Welcome to our dedicated news page for Zai Lab (Ticker: ZLAB), a resource for investors and traders seeking the latest updates and insights on Zai Lab.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zai Lab's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zai Lab's position in the market.

News
Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
Rhea-AI Summary
Zai Lab Limited (ZLAB) announced Phase 1/2 TRIDENT-1 study data published in The New England Journal of Medicine demonstrate the potential of repotrectinib (TPX-0005) to overcome limitations of first-generation TKIs in terms of durability of responses and activity in ROS1 resistance mutations. The study showed robust intracranial activity in patients with ROS1-positive non-small cell lung cancer, with repotrectinib demonstrating high response rates and durable activity, including in patients with TKI-naïve and TKI-pretreated tumors, ROS1 G2032R resistance mutations, and brain metastases. The findings suggest repotrectinib as a next-generation treatment for ROS1+ NSCLC. The Center for Drug Evaluation of the National Medical Products Administration accepted the New Drug Application for repotrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC after granting priority review in May 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.37%
Tags
none
-
News
Zai Lab Announces Participation in January Investor Conference
Rhea-AI Summary
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will participate in the J.P. Morgan 42nd Annual Healthcare Conference on January 8, 2024, with a live webcast available on the Investor Relations page of Zai Lab’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
none
-
News
Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List
Rhea-AI Summary
Zai Lab Limited (ZLAB) announces the inclusion of VYVGART, NUZYRA, and ZEJULA in China's 2023 National Reimbursement Drug List (NRDL), providing patient access to important medications at reduced prices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.85%
Tags
none
News
Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
Rhea-AI Summary
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced a 22% y-o-y growth in product revenue for Q3 2023, reaching $69.2 million, with VYVGART sales of $4.9 million in China. The company's cash position stands at $822.2 million, and the stock market announcement highlights the successful launch of VYVGART and ZEJULA's leading position in hospital sales for ovarian cancer in China.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6%
Tags
earnings
-
News
Zai Lab Announces Participation in November Investor Conferences
Rhea-AI Summary
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announces participation in investor conferences in November 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.53%
Tags
none
-
News
Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023
Rhea-AI Summary
Zai Lab Limited to report Q3 2023 financial results and host conference call and webcast
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
earnings
News
Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China
Rhea-AI Summary
Zai Lab's efgartigimod SC granted Breakthrough Therapy Designation for CIDP treatment, showing significant efficacy and favorable safety profile
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
none
-
News
Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China
Rhea-AI Summary
Zai Lab receives Breakthrough Therapy Designation for repotrectinib in China for the treatment of advanced solid tumors with NTRK gene fusion. The designation supports repotrectinib as a potential first-in-class treatment for patients in China. NTRK is estimated to be an oncogenic driver in approximately 0.5% of patients with advanced solid tumors. Zai Lab looks forward to bringing this important medicine to patients in need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.39%
Tags
none
-
News
Zai Lab Announces Participation in September Investor Conferences
Rhea-AI Summary
Zai Lab Limited to participate in investor conferences in September 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.34%
Tags
none
News
Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates
Rhea-AI Summary
Zai Lab Limited announced financial results for Q2 2023, reporting total product revenue of $68.9 million, a 45% YoY growth. The company received approval in China for VYVGART as the first-and-only FcRn blocker for gMG. They also met the primary endpoint in the ADHERE trial for VYVGART Hytrulo in CIDP. The company has a cash position of $876.4 million as of June 30, 2023. Zai Lab expects significant revenue growth and margin expansion over the next five years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.58%
Tags
earnings
Stock ZLAB logo
Zai Lab Limited

Nasdaq:ZLAB

ZLAB Rankings

#2140 Ranked by Market Cap
#1648 Ranked by Stock Gains
N/A Ranked by Dividends

ZLAB Stock Data

1.46B
887.81M
1.83%
44.84%
3.9%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
China (Mainland)
Shanghai

About ZLAB

zai lab is a biopharmaceutical company dedicated to discovering, developing and commercializing innovative medicines. our vision is to address the largest unmet medical needs and transform patients’ lives around the world. we take a unique approach to combine both in-licensed products and internal r&d; to achieve a rich pipeline. we believe our drug candidates can be truly disease modifying and bring significant benefits to patients. the company was founded in 2013 by a group of industry veterans. the founders are known as pioneers in china’s fast advancing biotech industry with a proven track record for successful chinese cfda and us fda filings and approvals. our senior management team introduced fast regulatory approval pathways in china and developed a variety of partnership models with multinational pharmaceutical companies. we endeavor to conduct world class clinical development in china and beyond. zai lab has strong backing from a leading group of healthcare investors. our inve